Gilead Sciences (NASDAQ:GILD) Given New $150.00 Price Target at Morgan Stanley

Gilead Sciences (NASDAQ:GILD) had its price objective trimmed by Morgan Stanley from $151.00 to $150.00 in a report released on Tuesday morning,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on the company. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Citigroup lifted their target price on Gilead Sciences from $135.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. TD Cowen boosted their price target on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $133.16.

Gilead Sciences Stock Down 0.7%

GILD stock opened at $121.76 on Tuesday. The firm’s 50-day moving average is $123.25 and its two-hundred day moving average is $117.85. The company has a market capitalization of $151.07 billion, a price-to-earnings ratio of 18.88, a price-to-earnings-growth ratio of 0.64 and a beta of 0.33. Gilead Sciences has a 52 week low of $89.83 and a 52 week high of $128.70. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same period last year, the firm posted $2.02 earnings per share. The business’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were paid a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Insiders Place Their Bets

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the sale, the chief executive officer owned 581,203 shares in the company, valued at $69,389,826.17. The trade was a 1.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the transaction, the director directly owned 8,920 shares of the company’s stock, valued at $1,115,713.60. This represents a 35.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 130,757 shares of company stock valued at $16,205,752 over the last 90 days. 0.27% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Avaii Wealth Management LLC acquired a new position in shares of Gilead Sciences in the fourth quarter worth $247,000. Global X Japan Co. Ltd. grew its stake in Gilead Sciences by 334.6% in the fourth quarter. Global X Japan Co. Ltd. now owns 48,825 shares of the biopharmaceutical company’s stock valued at $5,993,000 after purchasing an additional 37,591 shares in the last quarter. Mather Group LLC. increased its position in Gilead Sciences by 21.2% in the 4th quarter. Mather Group LLC. now owns 16,236 shares of the biopharmaceutical company’s stock worth $1,993,000 after purchasing an additional 2,837 shares during the last quarter. Parsons Capital Management Inc. RI purchased a new stake in shares of Gilead Sciences during the 4th quarter worth about $717,000. Finally, Kathmere Capital Management LLC lifted its holdings in shares of Gilead Sciences by 6.6% during the 4th quarter. Kathmere Capital Management LLC now owns 28,247 shares of the biopharmaceutical company’s stock valued at $3,467,000 after buying an additional 1,758 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: CVS added Gilead’s new HIV prevention shot to its commercial drug coverage lists, which should improve payer access and uptake for the new product if national rollout continues — a direct commercial catalyst for future revenue. Gilead’s new HIV prevention shot added to CVS’s drug coverage lists, CEO says
• Positive Sentiment: Major banks (UBS and Citi) turned bullish on Gilead this week, boosting investor sentiment and providing institutional support that can help the share price if their theses around HIV and oncology execution hold. UBS and Citi go bullish on Gilead Sciences (GILD)
• Positive Sentiment: BMO’s analyst reiterated a buy view, pointing to durable HIV leadership and a de‑risking oncology pipeline — analyst conviction like this supports a constructive medium-term outlook. Gilead Sciences: Durable HIV Leadership and De‑Risking Oncology Pipeline Support Compelling Buy-Rated Risk‑Reward
• Positive Sentiment: New OncoNano drug-delivery collaboration highlighted as a potential game-changer in the bull case — any successful pipeline partnerships or delivery wins would materially lift upside for Gilead’s oncology exposure. The Bull Case For Gilead Sciences (GILD) Could Change Following New OncoNano Drug-Delivery Collaboration
• Positive Sentiment: CEO Daniel O’Day’s JPMorgan presentation and the company transcript emphasized a deep pipeline (company calls it the most robust in its history) and new HIV assets like Yeztugo — that messaging supports upside from product launches and pipeline milestones. Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Morgan Stanley trimmed its price target slightly (from $151 to $150) but left an Overweight rating in place — a marginal PT cut that still implies sizable upside, so impact on fundamentals is limited. Gilead Sciences had its price target lowered by analysts at Morgan Stanley
• Neutral Sentiment: Short-interest data published for January appears inconsistent/immaterial (reports of “large increase” but values show zero), so there’s no clear short-squeeze pressure or bearish signal from short data at this time.
• Neutral Sentiment: Recent commentary and summaries (Seeking Alpha/Zacks) note outperformance vs. market on some sessions, but these are incremental and do not by themselves signal a durable trend change. Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth Knowing

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.